Presence of DFS pattern should not be used to indiscriminately exclude presence of a rheumatic disease based on retrospective study in Abs 0814. RA, SS and Raynaud's ICD10 codes were higher among DFS pattern ANA per chart review. #ACR22 @RheumNow https://t.co/mLtppvR4dk https://t.co/6Lukxntqe7

Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA. Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity. @RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M

The greater the PsAID score, the more likely escalation in PsA treatment. Noted significant correlation between PsAID and physician global scores. Do you use PsAID in your clinic? Abs 1028 #ACR22 @RheumNow https://t.co/gcjm2XgPE3 https://t.co/bKPtXz5Nw8

Abstr #1494 determinants of clinically important worsening (CIW) of early axSpA - CIW = ASDAS ↑ > 0.9 b/w 2 visits - Tender Joint count and ASAS-NSAID score associated w/ CIW - MRI SI Jt inflammation & structural damage predictive of CIW @RheumNow #ACR22 https://t.co/Dgeh25BaWM

Global survey of rheumatic irAE people (me included) Standard case Variable answers, broadly distributed none are wrong We'll move from expert extrapolation of concepts to data-driven answers, with the right foundations👍 ABST0776 @MDAndersonNews @msalmazor #ACR22 @RheumNow https://t.co/5gMzWuCXd7

BASDAI and ASDAS performed similarly in axPsA pts, both demonstrating weak correlations w/ peripheral arthritis and moderate/strong correlations w/ pt fatigue and pain. Abs 1037 #ACR22 @RheumNow https://t.co/WRQx1hkIll https://t.co/kJVIWyVv2w

3 yr interim RELIANCE study analysis shows long-term CAN tx is safe and effective in CAPS regardless of the underlying mutation and TRAPS. Abs 0812 #ACR22 @RheumNow https://t.co/pgSq1IICJK and https://t.co/Y2NUpgXGPL https://t.co/j9DMFF7V8S

Exposure to DMARDs prior to ICI treatment was not associated with 2-year crude mortality rates. Abs 0764 #ACR22 @RheumNow https://t.co/WvTy84Si7u https://t.co/X4RvYAVSMC

Window of opportunity in PsA CorEvitas registry: Early initiators had more severe disease & worse PROs but if DMARD therapy initiated within 1 yr: RR=2 MDA achievement & higher reduction of CDAI https://t.co/Xm9i7aiq85 Abs#1493 #ACR22 @Rheumnow https://t.co/RAGoHeuSIg

Performance BASDAI & ASDAS in evaluating PsA axial symptoms? 400+ pts DISCOVER 1&2 Weak correlations w/ peripheral arthritis Moderate/strong correlations w/ fatigue & pain Both perform similarly but do they perform well enough? https://t.co/alnrEXtydp Abs#1037 #ACR22 @Rheumnow https://t.co/Zuf1FruneK